A price concession of £34.30 per device of ALK-Abello Ltd was granted by the Department of Health and Social Care (DHSC) for all generic prescriptions for ‘Adrenaline 150micrograms/0.15ml (1 in 1000) solution for injection pre-filled disposable devices’ (Photo: iStock).

The branded prescriptions for Jext 150mcg/0.15ml and Jext 300mcg/0.3ml (1 in 1,000) solution for injection auto-injectors will be reimbursed at the price of £34.30 for August 2020 prescriptions, the Pharmaceutical Services Negotiating Committee (PSNC) said.

A price concession of £34.30 per device was granted by the Department of Health and Social Care (DHSC) for all generic prescriptions for ‘Adrenaline 150micrograms/0.15ml (1 in 1000) solution for injection pre-filled disposable devices’ for August.

While the price concession will only apply to generically written prescriptions, PSNC said it has requested the DHSC to make an exception for both strengths of Jext as adrenaline auto-injectors are commonly prescribed by brand name to ensure that patients receive a device they are familiar with.

The decision by the DHSC will “help to avoid contractors dispensing these items as branded prescriptions at loss during the month of August and also avoid the need for contractors to obtain replacement generically written prescriptions for accurate reimbursement,” PSNC said.

The decision has retrospective effect as the list price of Jext changed from £23.99 to £34.40 on August 1, according to NHS dictionary of medicines and devices (dm+d).

Following the price change mechanism, any list price changes (up to and including the 8th of the month) for proprietary products and part VIIIA products where the price is based on a proprietary product, takes effect for any prescriptions dispensed in the following month.

In the case of Jext, the new reimbursement price would have only applied to prescriptions (branded or generic) dispensed from September.

If you want to share your stories and/or experiences with us, please send an email to [email protected]

LEAVE A REPLY